A mechanistic study to assess whether isoproterenol can reverse the negative chronotropic effect of fingolimod

Journal of Clinical Pharmacology

Volumn 48, Issue 3, 2008, Pages 303-310

  Kovarik, John M ^a   Riviere, Gilles Jacques ^a   Neddermann, Daniel ^a   Maton, Steve ^a   Hunt, Thomas L ^b   Schmouder, Robert L ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Pharmaceutical Product Development   (United States)

Author keywords

Drug interactions; Fingolimod; Heart rate; Immunomodulators; Isoproterenol

Indexed keywords

FINGOLIMOD; ISOPRENALINE; PLACEBO;

ADULT; ANXIETY; ARTICLE; BLOOD PRESSURE; CHRONOTROPISM; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG HALF LIFE; DRUG INFUSION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FLUSHING; HEADACHE; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HEART RATE; HUMAN; HUMAN EXPERIMENT; LYMPHOCYTE COUNT; MALE; NAUSEA; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SIDE EFFECT; SINGLE BLIND PROCEDURE; TELEMETRY; THORAX PAIN;

ADMINISTRATION, ORAL; ADRENERGIC BETA-AGONISTS; ADULT; AREA UNDER CURVE; ATRIAL FIBRILLATION; BRADYCARDIA; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; INFUSIONS, INTRAVENOUS; ISOPROTERENOL; MALE; PATIENT DROPOUTS; PROPYLENE GLYCOLS; RECEPTORS, LYSOSPHINGOLIPID; SPHINGOSINE; TACHYCARDIA; TIME FACTORS;

EID: 39149122460     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007312903     Document Type: Article

References (14)

1. Kappos L., Antel J., Comi G., et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006 ; 355: 1124-1140.
2. Brinkmann V., Lynch KR FTY720: targeting G-protein-coupled receptors for sphingosine 1-phosphate in transplantation and autoimmunity. Current Opin Immunol. 2002 ; 14: 569-575.
3. Massberg S., von Andrian UH Fingolimod and sphingosine-1-phosphate: modifiers of lymphocyte migration. N Engl J Med. 2006 ; 355: 1088-1091.
4. Baumruker T., Billich A., Brinkmann V. FTY720, an immunomodulatory sphingolipid mimetic: translation of a novel mechanism into clinical benefit in multiple sclerosis. Expert Opin Investig Drugs. 2007 ; 16: 283-289.
5. Hla T. Signaling and biological actions of sphingosine-1-phosphate Pharmacol Res. 2003 ; 47: 401-407.
6. Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther. 2007 ; 115: 84-105.
7. Koyrakh L., Lujan R., Colon J., et al. Molecular and cellular diversity of neuronal G-protein-gated potassium channels J Neurosci. 2005 ; 25: 11468-11478.
8. Guo J., MacDonell KL, Giles WR Effects of sphingosine 1-phosphate on pacemaker activity in rabbit sino-atrial node cells. Pflugers Arch. 1999 ; 438: 642-648.
9. Schmouder RL, Barilla D., Wang Y., et al. FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects. J Clin Pharmacol. 2006 ; 46: 895-904.
10. Kovarik JM, Schmouder RL, Barilla D., et al. Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects. Br J Clin Pharmacol. 2004 ; 57: 586-591.
11. Kovarik JM, Schmouder RL, Serra D., et al. FTY720 pharmacokinetics in mild to moderate hepatic impairment. J Clin Pharmacol. 2005 ; 45: 446-452.
12. Kovarik JM, Slade A., Voss B., et al. Ethnic sensitivity study of fingolimod in white and Asian subjects. Int J Clin Pharmacol Ther. 2007 ; 45: 98-109.
13. Field JM, Hazinski MF, Gilmore D, eds. Handbook of Emergency Cardiovascular Care for Healthcare Providers. Dallas, TX: American Heart Association ; 2006: 1-97.
14. Tolle M., Levkau B., Keul P., et al. Immunomodulator FTY720 induces eNOS-dependent arterial vasodilation via the lysosphingolipid receptor S1P3. Circ Res. 2005 ; 96: 913-920.